RE:RE:RE:RE:RE:RE:New article from La presse Looking at the article again, I think Luc is trying to say Thera’s global revenues will be around $400 million in 2020.
This could fit with the $1 Billion in total sales mentioned this week.
$1 Billion in global sales could mean just over $400 million in revenue for TH from Ibalizumab.
The majority of that would flow to the bottom line as profits....80% listed in the article.
So, let’s say profits of $300 million based on the above.
Forget about the dollar exchange rate for now and consider minimal dilution.
$300 million/80 million shares would be $3.75 in profits.
Multiple of 10 = SP $37.75
Multiple of 15 = SP $56
Multiple of 20 = SP $75
None of the above scenarios account for possible other high margin drugs.
bfw
jfm1330 wrote: First the article is not from La Presse, but from Les Affaires. It has many errors in it. The main item' I think, is that it confirms that a third drug is not going to be acquired before Ibalizumab approval. Tanguay said that they are at the stage of consulting doctors to have a clue about which minor HIV drug would be interesting to look at. As I wrote here before, I made quite extensive researches on the net to try to identify a target and I found nothing. It is likely to be a drug that treat side-effects of HIV, not an ARV drug. But I think that even though Tanguay said they have somebody dedicated to this search, a deal will not be struck in the near future.
The other very interesting point is the fact that Tanguay is no longer afraid to make bold statements about the level of sales he expect. It is very clear now that they expect much more than the revenues generated by Egrifta. Since Thera's share is 48% plus milestones,It means that the global revenues will be well above 100 M$ or even 200 M$. But as he said, if approved they will need to execute.
Add to that the coordinated move of this week by the management to buy shares on the open market that only add to what they already own. The message of confidence is very clear.